Pneumonia is inflammation of the lungs caused by bacteria, viruses, any in some cases, chemical irritants. It is a serious infection in which air sacs in the lungs fill with liquid making it difficult to breathe. Many different types of pneumonia exist, however, they are preventable through routine vaccines.

This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. This study will include both full-term infants (≥37 weeks gestational age) and premature infants (<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess immunogenicity and safety following administration of V114 or Prevnar 13™.

Register Today!.

Trial Information

Start Date13 December 2018
End Date08 January 2021
Trial Duration16 to 20 Months
Number of Visits6 In Person, 5 Telephone
Lead CRCAdam Pawluch

For additional information on this trial contact: